{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:36:45Z","timestamp":1791466605501,"version":"4.3.4"},"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T00:00:00Z","timestamp":1560384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002999","name":"Ministerie van Volksgezondheid, Welzijn en Sport","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002999","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministerie van Economische Zaken en Klimaat"},{"DOI":"10.13039\/501100002998","name":"College ter Beoordeling van Geneesmiddelen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002998","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0218014","type":"journal-article","created":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T13:36:37Z","timestamp":1560432997000},"page":"e0218014","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":48,"title":["A standardised framework to identify optimal animal models for efficacy assessment in drug development"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5606-6525","authenticated-orcid":true,"given":"Guilherme","family":"S. Ferreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5331-2698","authenticated-orcid":true,"given":"D\u00e9sir\u00e9e H.","family":"Veening-Griffioen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1218-193X","authenticated-orcid":true,"given":"Wouter P. C.","family":"Boon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen H. M.","family":"Moors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine C.","family":"Gispen-de Wied","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huub","family":"Schellekens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J. K.","family":"van Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,6,13]]},"reference":[{"key":"ref1","unstructured":"European Commission. Directive 2004\/27\/EC of the European Parliament and of the Council of 31 March 2004 Amending Directive 2001\/83\/EC on the Community Code Relating to Medicinal Products for Human Use [Internet]. 2004 [cited 2018 Jun 13]. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/ec.europa.eu\/health\/sites\/health\/files\/files\/eudralex\/vol-1\/dir_2004_27\/dir_2004_27_en.pdf\" xlink:type=\"simple\">https:\/\/ec.europa.eu\/health\/sites\/health\/files\/files\/eudralex\/vol-1\/dir_2004_27\/dir_2004_27_en.pdf<\/ext-link>"},{"key":"ref2","unstructured":"US Congress. Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [Internet]. 1938 [cited 2018 Jun 13]. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.fda.gov\/RegulatoryInformation\/LawsEnforcedbyFDA\/FederalFoodDrugandCosmeticActFDCAct\/default.htm\" xlink:type=\"simple\">https:\/\/www.fda.gov\/RegulatoryInformation\/LawsEnforcedbyFDA\/FederalFoodDrugandCosmeticActFDCAct\/default.htm<\/ext-link>"},{"issue":"14","key":"ref3","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1001\/jama.296.14.1731","article-title":"Translation of Research Evidence From Animals to Humans","volume":"296","author":"DG Hackam","year":"2006","journal-title":"JAMA [Internet]"},{"issue":"3","key":"ref4","first-page":"1","article-title":"Can Animal Models of Disease Reliably Inform Human Studies?","volume":"7","author":"HB van der Worp","year":"2010","journal-title":"PLoS Med [Internet]"},{"issue":"7438","key":"ref5","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1136\/bmj.328.7438.514","article-title":"Where is the evidence that animal research benefits humans?","volume":"328","author":"P Pound","year":"2004","journal-title":"BMJ Br Med J"},{"key":"ref6","first-page":"1","article-title":"We need better animal research, better reported","volume":"360","author":"F Godlee","year":"2018","journal-title":"BMJ (Online)"},{"issue":"7586","key":"ref7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1136\/bmj.39048.407928.BE","article-title":"Comparison of treatment effects between animal experiments and clinical trials: systematic review","volume":"334","author":"P Perel","year":"2007","journal-title":"BMJ Br Med J [Internet]"},{"key":"ref8","unstructured":"Top Institute Pharma. Predictive Value of Animal Testing Research [Internet]. [cited 2018 May 7]. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.tipharma.com\/pharmaceutical-research-projects\/completed-projects\/predictive-value-of-animal-testing\/\" xlink:type=\"simple\">http:\/\/www.tipharma.com\/pharmaceutical-research-projects\/completed-projects\/predictive-value-of-animal-testing\/<\/ext-link>"},{"issue":"3","key":"ref9","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.yrtph.2012.09.002","article-title":"The ability of animal studies to detect serious post marketing adverse events is limited","volume":"64","author":"PJK van Meer","year":"2012","journal-title":"Regul Toxicol Pharmacol"},{"issue":"10","key":"ref10","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/nbt.2709","article-title":"The value of non-human primates in the development of monoclonal antibodies","volume":"31","author":"PJK van Meer","year":"2013","journal-title":"Nat Biotechnol [Internet]"},{"issue":"2","key":"ref11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.yrtph.2013.07.014","article-title":"The risk-based approach to ATMP development\u2014Generally accepted by regulators but infrequently used by companies","volume":"67","author":"M Kooijman","year":"2013","journal-title":"Regul Toxicol Pharmacol [Internet]"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.techfore.2017.02.003","article-title":"How institutional logics hamper innovation: The case of animal testing","volume":"118","author":"M Kooijman","year":"2017","journal-title":"Technol Forecast Soc Change"},{"issue":"4","key":"ref13","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.drudis.2014.11.009","article-title":"Contribution of animal studies to evaluate the similarity of biosimilars to refrence products","volume":"20","author":"PJK van Meer","year":"2015","journal-title":"Drug Discov Today"},{"issue":"3","key":"ref14","first-page":"245","article-title":"Validating Animal Models for Preclinical Research: A Scientific and Ethical Discussion","volume":"38","author":"OE Varga","year":"2010","journal-title":"Atla"},{"issue":"22","key":"ref15","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1111\/bph.14485","article-title":"Preclinical efficacy in therapeutic area guidelines from the U.S. Food and Drug Administration and the European Medicines Agency: a cross-sectional study","volume":"175","author":"H Langhof","year":"2018","journal-title":"Br J Pharmacol"},{"issue":"2","key":"ref16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nrd3375","article-title":"Trial watch: phase III and submission failures: 2007\u20132010","volume":"10","author":"J Arrowsmith","year":"2011","journal-title":"Nat Rev Drug Discov [Internet]"},{"issue":"8","key":"ref17","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nrd4090","article-title":"Trial Watch: Phase II and Phase III attrition rates 2011\u20132012","volume":"12","author":"J Arrowsmith","year":"2013","journal-title":"Nat Rev Drug Discov [Internet]"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nbt.2786","article-title":"Clinical development success rates for investigational drugs","volume":"32","author":"M Hay","year":"2014","journal-title":"Nat Biotech [Internet]"},{"issue":"12","key":"ref19","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1001\/jamainternmed.2016.6008","article-title":"Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results","volume":"176","author":"TJ Hwang","year":"2016","journal-title":"JAMA Intern Med [Internet]"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/jnc.13844","article-title":"The impact of fraudulent and irreproducible data to the translational research crisis\u2013solutions and implementation","volume":"139","author":"JB Schulz","year":"2016","journal-title":"J Neurochem"},{"issue":"6","key":"ref21","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/j.1553-2712.2003.tb00056.x","article-title":"Emergency medicine animal research: Does use of randomization and blinding affect the results?","volume":"10","author":"V Bebarta","year":"2003","journal-title":"Acad Emerg Med"},{"issue":"7419","key":"ref22","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nature11556","article-title":"A call for transparent reporting to optimize the predictive value of preclinical research","volume":"490","author":"SC Landis","year":"2012","journal-title":"Nature"},{"issue":"7","key":"ref23","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nrd4090-c1","article-title":"Can you trust your animal study data?","volume":"13","author":"IS Peers","year":"2014","journal-title":"Nat Rev Drug Discov [Internet]"},{"issue":"9","key":"ref24","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/nrd3439-c1","article-title":"Believe it or not: How much can we rely on published data on potential drug targets?","volume":"10","author":"F Prinz","year":"2011","journal-title":"Nat Rev Drug Discov [Internet]"},{"issue":"7391","key":"ref25","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/483531a","article-title":"Drug development: Raise standards for preclinical cancer research","volume":"483","author":"CG Begley","year":"2012","journal-title":"Nature [Internet]"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.bbr.2017.06.018","article-title":"Effect of a change in housing conditions on body weight, behavior and brain neurotransmitters in male C57BL\/6J mice","volume":"333","author":"N Pasquarelli","year":"2017","journal-title":"Behav Brain Res"},{"issue":"6","key":"ref27","doi-asserted-by":"crossref","first-page":"e1000412","DOI":"10.1371\/journal.pbio.1000412","article-title":"Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research","volume":"8","author":"C Kilkenny","year":"2010","journal-title":"PLOS Biol [Internet]"},{"key":"ref28","first-page":"1","article-title":"PREPARE: guidelines for planning animal research and testing","author":"AJ Smith","year":"2017","journal-title":"Lab Anim [Internet]"},{"issue":"2","key":"ref29","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/jebm.12198","article-title":"The use of GRADE approach in systematic reviews of animal studies","volume":"9","author":"D Wei","year":"2016","journal-title":"J Evid Based Med"},{"key":"ref30","unstructured":"EQIPD. European Quality In Preclinical Data [Internet]. [cited 2018 Oct 4]. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/quality-preclinical-data.eu\/\" xlink:type=\"simple\">https:\/\/quality-preclinical-data.eu\/<\/ext-link>"},{"issue":"2","key":"ref31","first-page":"240","article-title":"Animal model of depression. I. Review of evidence: implications for research","volume":"21","author":"WT McKinney Jr.","year":"1969","journal-title":"ArchGenPsychiatry [Internet]"},{"issue":"1","key":"ref32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00427414","article-title":"The validity of animal models of depression","volume":"83","author":"P Willner","year":"1984","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"ref33","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bcp.2013.08.006","article-title":"Animal models of human disease: Challenges in enabling translation","volume":"87","author":"P McGonigle","year":"2014","journal-title":"Biochem Pharmacol [Internet]"},{"issue":"7\u20138","key":"ref34","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.drudis.2006.02.005","article-title":"Strategies to optimize the validity of disease models in the drug discovery process","volume":"11","author":"F Sams-Dodd","year":"2006","journal-title":"Drug Discov Today"},{"issue":"1","key":"ref35","first-page":"5","article-title":"Animal models in translational medicine: Validation and prediction","volume":"2","author":"T Denayer","year":"2014","journal-title":"New Horizons Transl Med [Internet]"},{"issue":"1","key":"ref36","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2648.2007.04569.x","article-title":"The qualitative content analysis process","volume":"62","author":"S Elo","year":"2008","journal-title":"J Adv Nurs"},{"issue":"1","key":"ref37","first-page":"1","article-title":"SYRCLE\u2019s risk of bias tool for animal studies","volume":"14","author":"CR Hooijmans","year":"2014","journal-title":"BMC Med Res Methodol [Internet]"},{"key":"ref38","unstructured":"OECD. Guidance document on the validation and international acceptance of new or updated test methods for hazard assessment [Internet]. Vol. 34. 2005 [cited 2016 Jul 4]. p. 1\u201396. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.oecd.org\/officialdocuments\/publicdisplaydocumentpdf\/?doclanguage=en&cote=env\/jm\/mono(2005)14\" xlink:type=\"simple\">http:\/\/www.oecd.org\/officialdocuments\/publicdisplaydocumentpdf\/?doclanguage=en&amp;cote=env\/jm\/mono(2005)14<\/ext-link>"},{"key":"ref39","unstructured":"ICH. S5(R3) Revision of S5 Guideline on Detection of Toxicity to Reproduction for Human Pharmaceuticals [Internet]. 2017 [cited 2018 Mar 17]. p. 1\u201363. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Safety\/S5\/S5-R3EWG_Step2_Guideline_2017_0705.pdf\" xlink:type=\"simple\">http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Safety\/S5\/S5-R3EWG_Step2_Guideline_2017_0705.pdf<\/ext-link>"},{"issue":"4","key":"ref40","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/phar.1909","article-title":"Advances in the Treatment of Duchenne Muscular Dystrophy: New and Emerging Pharmacotherapies","volume":"37","author":"AM Reinig","year":"2017","journal-title":"Pharmacotherapy"},{"issue":"3","key":"ref41","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1242\/dmm.018424","article-title":"Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy","volume":"8","author":"JW McGreevy","year":"2015","journal-title":"Dis Model Mech"},{"issue":"8","key":"ref42","first-page":"1314","article-title":"Dystrophin-deficient large animal models: Translational research and exon skipping","volume":"7","author":"X Yu","year":"2015","journal-title":"Am J Transl Res"},{"issue":"8","key":"ref43","first-page":"e3081","article-title":"Systematic review of the empirical evidence of study publication bias and outcome reporting bias","volume":"3","author":"K Dwan","year":"2008","journal-title":"PLoS Biol [Internet]"},{"issue":"3","key":"ref44","doi-asserted-by":"crossref","first-page":"e1000344","DOI":"10.1371\/journal.pbio.1000344","article-title":"Publication bias in reports of animal stroke studies leads to major overstatement of efficacy","volume":"8","author":"ES Sena","year":"2010","journal-title":"PLoS Biol"},{"issue":"6","key":"ref45","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/nbt.2261","article-title":"Should preclinical studies be registered?","volume":"30","author":"J Kimmelman","year":"2012","journal-title":"Nat Biotechnol"},{"issue":"9","key":"ref46","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/eci.12299","article-title":"All preclinical trials should be registered in advance in an online registry","volume":"44","author":"SJ Jansen of Lorkeers","year":"2014","journal-title":"Eur J Clin Invest"},{"issue":"4","key":"ref47","doi-asserted-by":"crossref","first-page":"e2004879","DOI":"10.1371\/journal.pbio.2004879","article-title":"Preclinical efficacy studies in investigator brochures: Do they enable risk\u2013benefit assessment?","volume":"16","author":"S Wieschowski","year":"2018","journal-title":"PLOS Biol"},{"key":"ref48"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0220325","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T00:00:00Z","timestamp":1563753600000}}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0218014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T18:50:19Z","timestamp":1588963819000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0218014"}},"subtitle":[],"editor":[{"given":"Malcolm R.","family":"Macleod","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,6,13]]},"references-count":48,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,6,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0218014","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/382366","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,13]]}}}